Published • loading... • Updated
EMBO-02 FIH Study of Arsenal’s NeoCast Liquid Embolic Meets Endpoints in Treatment of cSDH
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
EMBO-02 FIH Study of Arsenal’s NeoCast Liquid Embolic Meets Endpoints in Treatment of cSDH
July 22, 2026—Arsenal Medical announced late-breaking results from the EMBO-02 first-in-human (FIH) clinical study, which is evaluating the company’s NeoCast liquid embolic for middle meningeal artery embolization (MMAe) to treat chronic subdural hematoma (cSDH). The company stated that NeoCast is a next-generation, shear-responsive, solvent-free, nonadhesive liquid embolic that is engineered to reach distal microvasculature without causing pain…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
